Antibodies News and Research

RSS

New mouse model of SARS-CoV-2 infection reflects features of human infection

Now, a new preprint research paper posted to the bioRxiv server reports the development of a modified mouse model that allows productive SARS-CoV-2 infection of the mouse lungs, as well as the exploration of type I and III interferon responses in this condition.

14 Feb 2021

SARS-CoV-2's resistance to remdesivir in vitro

A new preprint research paper posted to the bioRxiv server discusses the emergence of mutations in the SARS-CoV-2 virus, allowing it to escape the effects of the most commonly used antiviral drug, remdesivir.

14 Feb 2021

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Researchers from Cuba, China, and France have demonstrated the potential of coupling a viral antigen with the tetanus toxoid protein as a vaccination approach to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

14 Feb 2021

Using a smartphone-based microscope for detecting single molecules and diagnosing diseases

Biomarkers play a central role in the diagnosis of disease and assessment of its course. Among the markers now in use are genes, proteins, hormones, lipids and other classes of molecules.

13 Feb 2021

The Future of Environmental and Food Monitoring

NewsMed interviews Professor Antje Baeumner about the future of food and environmental monitoring, the subject of her 2021 Pittcon presentation.

From Pittcon 12 Feb 2021

Study offers new protocols for high-quality SARS-CoV-2 genomic sequencing

Researchers at the Southern Illinois University, U.S.A. have presented a comprehensive and well-validated set of working protocols for sequencing high-quality SARS-CoV-2 genomes in high throughput from patient samples.

12 Feb 2021

People previously infected with COVID-19 respond strongly to one dose of Pfizer vaccine

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those previously infected with SARS-CoV-2 is still not completely understood.

12 Feb 2021

New technology can help develop diagnostic tests for multiple sclerosis

Multiple sclerosis (MS) is the most common neurological disease in young adults, affecting more than 2 million individuals worldwide, with about 1500 cases in Estonia. About 20% of MS patients experience optic neuritis (ON) as the presenting symptom, but not all ON patients develop MS.

12 Feb 2021

Researchers identify a pathway used by filoviruses to enter cells

It was once thought that Ebola and related filoviruses were more or less contained to Central Africa.

11 Feb 2021

SARS-CoV-2 evolves antibody resistance in immunocompromised patient

Researchers in the United States who tracked the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient found that convalescent plasma therapy was associated with the emergence of viral variants that were less susceptible to neutralizing antibodies.

11 Feb 2021

New gut microbiome-based approach may have translational potential for cancer immunotherapy

Scientists from Nanjing University and the University of Macau have devised a new approach to extend the survival of transplanted probiotics in vivo, enhancing the efficacy of cancer chemo-/immunotherapies in mice.

11 Feb 2021

Breastfeeding women produce COVID-19 antibodies that neutralize the virus

Breastfeeding women with COVID-19 do not pass along the SARS-CoV-2 virus in their milk but do transfer milk-borne antibodies that are able to neutralize the virus, a multi-institutional team of researchers led by the University of Idaho reported.

11 Feb 2021

Scientists present new outlook on latest trends in peptide drug discovery and development

Currently there are more than 80 peptide drugs on the global market and about twice as many in clinical development.

10 Feb 2021

Exposure to seasonal coronaviruses does not produce antibodies that protect against SARS-CoV-2

Past exposure to seasonal coronaviruses (CoVs), which cause the common cold, does not result in the production of antibodies that protect against the novel coronavirus SARS-CoV-2, according to a study led by Scott Hensley, PhD, an associate professor of Microbiology at the Perelman School of Medicine at the University of Pennsylvania.

10 Feb 2021

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Researchers at the NYU Grossman School of Medicine have shown that a second dose of the Pfizer-BioNTech BNT162b2 vaccine may not offer any additional protection against coronavirus disease 2019 (COVID-19) over one dose among individuals previously infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Feb 2021

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Researchers at the Polish Academy of Sciences in Warsaw have identified a substrain of the recently emerged B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may confer resistance to antibody neutralization.

10 Feb 2021

Freiburg immunologists decipher anti-cancer drug's mode of operation

Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works.

10 Feb 2021

Taking Advantage of Measuring Molecular Collisional Cross-Sections in Pharma

News-Medical talks to Mike Greig, Director of Pharma at Bruker, about why measuring collisional cross-sections is beneficial to developing new drugs.

From Bruker Life Sciences Mass Spectrometry 10 Feb 2021

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.

10 Feb 2021

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

Researchers at Northwestern University have noted high rates of asymptomatic and mild infection in a large community-based cohort and low levels of anti-SARS-CoV-2 immunoglobulin G antibody (IgG) in the general population of previously exposed people.

10 Feb 2021

Antibodies News and Research

New mouse model of SARS-CoV-2 infection reflects features of human infection

SARS-CoV-2's resistance to remdesivir in vitro

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Using a smartphone-based microscope for detecting single molecules and diagnosing diseases

The Future of Environmental and Food Monitoring

Study offers new protocols for high-quality SARS-CoV-2 genomic sequencing

People previously infected with COVID-19 respond strongly to one dose of Pfizer vaccine

New technology can help develop diagnostic tests for multiple sclerosis

Researchers identify a pathway used by filoviruses to enter cells

SARS-CoV-2 evolves antibody resistance in immunocompromised patient

New gut microbiome-based approach may have translational potential for cancer immunotherapy

Breastfeeding women produce COVID-19 antibodies that neutralize the virus

Scientists present new outlook on latest trends in peptide drug discovery and development

Exposure to seasonal coronaviruses does not produce antibodies that protect against SARS-CoV-2

Second dose of Pfizer-BioNTech COVID-19 vaccine may not benefit previously infected individuals

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Freiburg immunologists decipher anti-cancer drug's mode of operation

Taking Advantage of Measuring Molecular Collisional Cross-Sections in Pharma

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Study finds low SARS-CoV-2 antibody responses in asymptomatic and mild COVID-19 cases

Immunology eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News